Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
4.
J Eur Acad Dermatol Venereol ; 36(9): 1564-1567, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-35426175

RESUMEN

BACKGROUND: Melanomas developing on anatomic sites other than the trunk and extremities have a special pathogenetic and mutational profile, morphologic characteristics and biologic behaviour. OBJECTIVE: By retrospectively screening the databases of our centres, we aimed to investigate the dermatoscopic morphology of early scalp melanoma, including in situ and invasive tumours with a Breslow thickness up to 1 mm. METHODS: The databases of three specialized centres for skin cancer diagnosis and management in Greece were retrospectively evaluated to retrieve dermatoscopic images of scalp melanomas. Patients' age and sex were recorded, as well as the precise location of the tumour, using 6 possible sub-locations: frontal, parietal, occipital, temporal, nuchal scalp and vertex. The dermatoscopic images were evaluated by 3 independent investigators for the presence of pre-defined criteria. The dermatoscopic criteria included in the evaluation were selected based on available literature and were categorized in 2 groups: 'classic melanoma criteria' and 'lentigo maligna (LM) criteria'. RESULTS: Of 38 melanomas, 37 (97.4%) displayed brown colour and 23 (60.5%) displayed additional grey or blue colour. The most frequent dermatoscopic criteria were regression (18/38, 47.4%), grey dots/globules (17/38, 44.7%), atypical network (16/38, 42.1%), obliterated follicles (16/38, 42.1%) and angulated lines (15/38, 39.5%). Of 38 melanomas, 28 (73.7%) displayed at least 1 classic melanoma criterion plus at least 1 LM criterion. Of the remaining melanomas, 8 (21.1%) displayed only classic melanoma criteria, 1 (2.6%) only LM criteria and 1 (2.6%) did not exhibit any of the evaluated criteria. CONCLUSIONS: This study demonstrates that early scalp melanoma combines classic with LM criteria in terms of colours and structures.


Asunto(s)
Peca Melanótica de Hutchinson , Melanoma , Neoplasias Cutáneas , Dermoscopía/métodos , Humanos , Peca Melanótica de Hutchinson/patología , Melanoma/patología , Estudios Retrospectivos , Cuero Cabelludo/patología , Neoplasias Cutáneas/patología
6.
Clin Exp Dermatol ; 47(1): 157-158, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34288056

RESUMEN

Several individuals have developed delayed localized cutaneous vaccine reactions to the two novel mRNA Covid-19 vaccines. Clinical and histopathologic results of this case series study confirm that the localized injection-site reactions to the mRNA COVID-19 vaccines are delayed hypersensitivity reactions that, unlike immediate hypersensitivity reactions, are not a contraindication to vaccination.


Asunto(s)
Vacuna nCoV-2019 mRNA-1273/efectos adversos , COVID-19/prevención & control , Hipersensibilidad a las Drogas/etiología , Hipersensibilidad Tardía/inducido químicamente , Reacción en el Punto de Inyección/etiología , Adulto , Anciano , Anciano de 80 o más Años , Hipersensibilidad a las Drogas/patología , Femenino , Humanos , Hipersensibilidad Tardía/patología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , SARS-CoV-2
11.
Clin Exp Dermatol ; 46(8): 1542-1544, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33811368

RESUMEN

Apremilast has been approved as an effective and safe treatment for psoriasis, but clinical trial results may differ from real-life data. This retrospective cross-sectional study evaluated the long-term efficacy and safety of apremilast in a Greek cohort of adult patients with psoriasis who had received at least one dose of apremilast between March 2016 and January 2021. The primary endpoint was the percentage of patients who achieved 75% reduction in Psoriasis Area Severity Index (PASI75) at Week 16. Absolute PASI, PASI90 (90% reduction) and adverse events were also recorded at various timepoints. In total, 102 patients (29.4% women, 70.6% men) with a mean ± SD age 55.94 ± 15.21 years were included. PASI75 and PASI90 were achieved by 20.8% and 1.98% of patients, respectively, at Week 16. According to our results, PASI90 achievement was significantly lower than that reported in clinical trials. The efficacy of apremilast increased gradually until Week 24, with further improvement noted in good responders up to Week 52.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Inhibidores de Fosfodiesterasa 4/uso terapéutico , Psoriasis/tratamiento farmacológico , Talidomida/análogos & derivados , Antiinflamatorios no Esteroideos/efectos adversos , Estudios Transversales , Esquema de Medicación , Femenino , Grecia , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de Fosfodiesterasa 4/efectos adversos , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Talidomida/efectos adversos , Talidomida/uso terapéutico , Resultado del Tratamiento
16.
J Eur Acad Dermatol Venereol ; 34(7): 1403-1414, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32678513

RESUMEN

Lichen planus (LP) is a chronic inflammatory and immune-mediated disease that affects the skin, hair, nails and mucous membranes. Although there is a broad clinical spectrum of lichen planus manifestations, the skin and oral cavity remain the major sites of involvement. A group of European dermatologists with a long-standing interest and expertise in lichen planus has sought to define therapeutic guidelines for the management of patients with LP. The clinical features, diagnosis and possible medications that clinicians can use, in order to control the disease, will be reviewed in this manuscript. The revised final version of the lichen planus guideline was passed on to the European Dermatology Forum (EDF) for a final consensus with the European Academy of Dermatology and Venereology (EADV).


Asunto(s)
Dermatología , Liquen Plano , Venereología , Academias e Institutos , Consenso , Humanos , Liquen Plano/diagnóstico , Liquen Plano/tratamiento farmacológico
19.
Br J Dermatol ; 182(2): 454-467, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31077336

RESUMEN

BACKGROUND: Over the last few years, several articles on dermoscopy of non-neoplastic dermatoses have been published, yet there is poor consistency in the terminology among different studies. OBJECTIVES: We aimed to standardize the dermoscopic terminology and identify basic parameters to evaluate in non-neoplastic dermatoses through an expert consensus. METHODS: The modified Delphi method was followed, with two phases: (i) identification of a list of possible items based on a systematic literature review and (ii) selection of parameters by a panel of experts through a three-step iterative procedure (blinded e-mail interaction in rounds 1 and 3 and a face-to-face meeting in round 2). Initial panellists were recruited via e-mail from all over the world based on their expertise on dermoscopy of non-neoplastic dermatoses. RESULTS: Twenty-four international experts took part in all rounds of the consensus and 13 further international participants were also involved in round 2. Five standardized basic parameters were identified: (i) vessels (including morphology and distribution); (ii) scales (including colour and distribution); (iii) follicular findings; (iv) 'other structures' (including colour and morphology); and (v) 'specific clues'. For each of them, possible variables were selected, with a total of 31 different subitems reaching agreement at the end of the consensus (all of the 29 proposed initially plus two more added in the course of the consensus procedure). CONCLUSIONS: This expert consensus provides a set of standardized basic dermoscopic parameters to follow when evaluating inflammatory, infiltrative and infectious dermatoses. This tool, if adopted by clinicians and researchers in this field, is likely to enhance the reproducibility and comparability of existing and future research findings and uniformly expand the universal knowledge on dermoscopy in general dermatology. What's already known about this topic? Over the last few years, several papers have been published attempting to describe the dermoscopic features of non-neoplastic dermatoses, yet there is poor consistency in the terminology among different studies. What does this study add? The present expert consensus provides a set of standardized basic dermoscopic parameters to follow when evaluating inflammatory, infiltrative and infectious dermatoses. This consensus should enhance the reproducibility and comparability of existing and future research findings and uniformly expand the universal knowledge on dermoscopy in general dermatology.


Asunto(s)
Dermatología , Enfermedades de la Piel , Consenso , Dermoscopía , Humanos , Estándares de Referencia , Reproducibilidad de los Resultados , Enfermedades de la Piel/diagnóstico por imagen
20.
J Eur Acad Dermatol Venereol ; 33(1): 79-83, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29869444

RESUMEN

BACKGROUND: Topical methyl aminolevulinate photodynamic therapy (MAL-PDT) with 3 h incubation is recommended as a field directed treatment. Skin pretreatment with ablative CO2 fractional laser (AFXL) prior to MAL-PDT enhances drug penetration and could minimize incubation time. OBJECTIVES: To evaluate and compare the safety and the preventive effect in the development of new non-melanocytic skin cancers (NMSCs) of AFXL-assisted MAL-PDT with 1-h incubation with that of conventional MAL-PDT in patients with clinical and histological signs of field cancerization. METHODS: Forty-two patients with two mirror cancerized areas of face or scalp were randomized to field treatment with 1-h incubation AFXL-assisted PDT or conventional PDT (CPDT). All patients underwent two treatment sessions 1 week apart. Irradiation was performed using a red light-emitting diode lamp at 37 J/cm2 . Patients were followed up at 3, 6, 9 and 12 months for the evaluation of development of new NMSCs lesions. RESULTS: All patients completed the study. There was no statistically significant difference with respect to the total number of new actinic keratoses at any point of follow-up as well as to the mean time of occurrence of new lesions between treatment fields. Both treatment regimens were safe and well tolerated. CONCLUSION: Ablative CO2 fractional laser pretreatment may be considered as an option for reducing photosensitizer occlusion time while providing the same preventative efficacy as CPDT in patients with field-cancerized skin.


Asunto(s)
Ácido Aminolevulínico/análogos & derivados , Carcinoma Basocelular/prevención & control , Carcinoma de Células Escamosas/prevención & control , Neoplasias Faciales/prevención & control , Queratosis Actínica/terapia , Láseres de Gas/uso terapéutico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/administración & dosificación , Cuero Cabelludo , Neoplasias Cutáneas/prevención & control , Administración Cutánea , Anciano , Anciano de 80 o más Años , Ácido Aminolevulínico/administración & dosificación , Ácido Aminolevulínico/farmacocinética , Terapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fotoquimioterapia/efectos adversos , Fármacos Fotosensibilizantes/farmacocinética , Absorción Cutánea , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...